Disheartened investors put UTHR shares to the rack on FREEDOM-C2 failure
This article was originally published in Scrip
Executive Summary
Shares of United Therapeutics dropped as low as 20.3%, or $9.89, on 24 August on the disappointing news that its investigational oral prostacyclin vasodilator drug treprostinil missed its primary endpoint in the firm's Phase III FREEDOM-C2 of improving the walking ability of patients with pulmonary arterial hypertension (PAH), a life-threatening disease that constricts the flow of blood through the pulmonary vasculature.